PROVECTUS BIOPHARMACEUTICALS, INC.

Provectus Biopharmaceuticals (PVCT) has logged zero cyber incidents and zero red-flag 8-K filings over the past 90 days, indicating operational stability in our near-term monitoring window. However, absence of recent events does not eliminate underlying risk—the biotech sector faces persistent dilution pressure and financing dependency that a 90-day snapshot cannot capture. The full $49 Report extends analysis to 12 months of filing history, layers in our proprietary dilution risk score and financing trajectory, and flags structural vulnerabilities including equity raise patterns and cash burn dynamics. The full $49 Report adds comprehensive 12-month context, quantified dilution risk scoring, and AI-driven signals on sustainability versus refinancing pressure.